ARTEMIS is the exclusive commercial license holder of the patent portfolio covering the use of the CreER gene switch.
These patents are issued in the US (US 6,040,430) and in Europe (EP 707 599). TaconicArtemis GmbH uses the techniques covered by these patents for its ArteMice®. Additionally TaconicArtemis GmbH is offering non exclusive internal research use licenses to these patents to pharmaceutical and biotechnology companies.
To enquire about sub-licensing possibilities please contact us at
services@artemispharma.de
TECHNOLOGY
